Japan Tissue Engineering (7774) · RiskDropped
Dependence on the Continuation of Collaboration with Universities and Research Institutions
First written in FY2016. 1 of 3 entries say "Restated". Latest entry: FY2024.
3entries
9years
0from disclosures
How it moved
Same theme, other companies
Risk of dependence on joint R&D counterparties and termination of agreementsA theme 17 companies write about · 20 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2025: 3 of 7 companies on the "Worse" side.
2 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 17 companies compared. The sentences above are computed from all 17.Full recordFilings, disclosures and news, newest first
- FY2024DroppedAnnual reportThe FY2024 business and other risks section does not identify dependence on continuing collaboration with universities and research institutions as a separate item.
- FY2020RestatedAnnual report
「The company promotes research and development activities in collaboration and cooperation with research institutions such as universities, medical institutions and healthcare professionals, but these activities may be affected by government policy and social conditions.」
While continuing collaboration with universities, research institutions and medical institutions, the company discloses risks to progress arising from government policy, social conditions, joint research and licensing negotiations. - FY2016First statedAnnual report
「The regenerative medicine pursued by the company requires close collaboration and cooperation with research institutions such as universities, as well as medical institutions and healthcare professionals.」
The filing indicates that discontinuation of joint research or failure to advance the transfer of rights could have a material impact on business strategy and performance.